ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor

R. Zanotti; A. Ambrosetti; M. Lestani; P. Ghia; C. Pattaro; A. Remo; F. Zanetti; S. Stella; O. Perbellini; G. Prato; G. Guida; F. Caligaris-Cappio; F. Menestrina; G. Pizzolo; M. Chilosi

doi:10.1038/sj.leu.2404458

ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor

R. Zanotti, A. Ambrosetti, M. Lestani, P. Ghia, C. Pattaro, A. Remo, F. Zanetti, S. Stella, O. Perbellini, G. Prato, G. Guida, F. Caligaris-Cappio, F. Menestrina, G. Pizzolo, M. Chilosi

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and β2-microglobulin serum levels and lymphocyte doubling time

Original language	English
Pages (from-to)	102-109
Number of pages	8
Journal	Leukemia
Volume	21
Issue number	1
DOIs	https://doi.org/10.1038/sj.leu.2404458
Publication status	Published - Jan 2007

ASJC Scopus subject areas

Hematology
Cancer Research

Access to Document

10.1038/sj.leu.2404458

Fingerprint Dive into the research topics of 'ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor'. Together they form a unique fingerprint.

Cite this

Zanotti, R., Ambrosetti, A., Lestani, M., Ghia, P., Pattaro, C., Remo, A., Zanetti, F., Stella, S., Perbellini, O., Prato, G., Guida, G., Caligaris-Cappio, F., Menestrina, F., Pizzolo, G., & Chilosi, M. (2007). ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia, 21(1), 102-109. https://doi.org/10.1038/sj.leu.2404458

ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. / Zanotti, R.; Ambrosetti, A.; Lestani, M.; Ghia, P.; Pattaro, C.; Remo, A.; Zanetti, F.; Stella, S.; Perbellini, O.; Prato, G.; Guida, G.; Caligaris-Cappio, F.; Menestrina, F.; Pizzolo, G.; Chilosi, M.

In: Leukemia, Vol. 21, No. 1, 01.2007, p. 102-109.

Research output: Contribution to journal › Article › peer-review

Zanotti, R, Ambrosetti, A, Lestani, M, Ghia, P, Pattaro, C, Remo, A, Zanetti, F, Stella, S, Perbellini, O, Prato, G, Guida, G, Caligaris-Cappio, F, Menestrina, F, Pizzolo, G & Chilosi, M 2007, 'ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor', Leukemia, vol. 21, no. 1, pp. 102-109. https://doi.org/10.1038/sj.leu.2404458

Zanotti, R. ; Ambrosetti, A. ; Lestani, M. ; Ghia, P. ; Pattaro, C. ; Remo, A. ; Zanetti, F. ; Stella, S. ; Perbellini, O. ; Prato, G. ; Guida, G. ; Caligaris-Cappio, F. ; Menestrina, F. ; Pizzolo, G. ; Chilosi, M. / ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. In: Leukemia. 2007 ; Vol. 21, No. 1. pp. 102-109.

@article{728cc93f1dbd4a92aa1d15bfdb94d9bc,

title = "ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor",

abstract = "Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and β2-microglobulin serum levels and lymphocyte doubling time ",

author = "R. Zanotti and A. Ambrosetti and M. Lestani and P. Ghia and C. Pattaro and A. Remo and F. Zanetti and S. Stella and O. Perbellini and G. Prato and G. Guida and F. Caligaris-Cappio and F. Menestrina and G. Pizzolo and M. Chilosi",

year = "2007",

month = jan,

doi = "10.1038/sj.leu.2404458",

language = "English",

volume = "21",

pages = "102--109",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor

AU - Zanotti, R.

AU - Ambrosetti, A.

AU - Lestani, M.

AU - Ghia, P.

AU - Pattaro, C.

AU - Remo, A.

AU - Zanetti, F.

AU - Stella, S.

AU - Perbellini, O.

AU - Prato, G.

AU - Guida, G.

AU - Caligaris-Cappio, F.

AU - Menestrina, F.

AU - Pizzolo, G.

AU - Chilosi, M.

PY - 2007/1

Y1 - 2007/1

N2 - Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and β2-microglobulin serum levels and lymphocyte doubling time

AB - Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and β2-microglobulin serum levels and lymphocyte doubling time

UR - http://www.scopus.com/inward/record.url?scp=33845538314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845538314&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404458

DO - 10.1038/sj.leu.2404458

M3 - Article

C2 - 17082778

AN - SCOPUS:33845538314

VL - 21

SP - 102

EP - 109

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -